<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifteen patients with the initial diagnosis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) received aggressive chemotherapy with high dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> or with a standard <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) regime </plain></SENT>
<SENT sid="1" pm="."><plain>Cases treated with aggressive chemotherapy were either younger individuals with refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) or patients, irrespective of age in advanced stages of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation or after evolution to frank <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), who did not have a major <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> at the time of presentation </plain></SENT>
<SENT sid="2" pm="."><plain>Age seemed to be the most important factor in determining the outcome of aggressive remission induction chemotherapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>: 86% of the patients less than 50 years entered complete remission, compared to only 25% in the older age group </plain></SENT>
<SENT sid="3" pm="."><plain>In spite of intensive consolidation therapy the duration of complete remission was short </plain></SENT>
<SENT sid="4" pm="."><plain>We conclude that young patients (less than 50 years) with excess of bone marrow blasts should be treated with aggressive chemotherapy even in the early stages of the disease </plain></SENT>
<SENT sid="5" pm="."><plain>Elderly patients in advanced stages of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> should be treated with less aggressive chemotherapy </plain></SENT>
</text></document>